Compare Constellation Energy Corporation (CEG) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs DexCom, Inc. — how do they compare? Constellation Energy Corporation trades at $258.54 (market cap $91.57B), while DexCom, Inc. trades at $76.3 (market cap $28.60B). The key difference: Constellation Energy Corporation is far larger — about 3.2× DexCom, Inc.'s market cap, and Constellation Energy Corporation pays a 0.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CEG | DXCM | |
|---|---|---|
Market Cap | $91.57B | $28.60B |
Sector | Energy | Health |
52-Week High | $403.95 | $89.53 |
52-Week Low | $236.50 | $54.84 |
Enterprise Value | $113.24B | $27.57B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
